| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE OF SEGMENT INFORMATION
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| |
|
For the Three Months Ended
April 30, |
|
|
For the Six Months Ended
April 30, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Net income/(loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(1,444 |
) |
|
$ |
(997 |
) |
|
$ |
(2,970 |
) |
|
$ |
(1,908 |
) |
| Cancer Vaccines |
|
|
(1,713 |
) |
|
|
(913 |
) |
|
|
(3,469 |
) |
|
|
(1,871 |
) |
| Other |
|
|
(23 |
) |
|
|
(397 |
) |
|
|
(31 |
) |
|
|
(882 |
) |
| Total |
|
$ |
(3,180 |
) |
|
$ |
(2,307 |
) |
|
$ |
(6,470 |
) |
|
$ |
(4,661 |
) |
| Net loss |
|
$ |
(3,180 |
) |
|
$ |
(2,307 |
) |
|
$ |
(6,470 |
) |
|
$ |
(4,661 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
3,467 |
|
|
$ |
2,770 |
|
|
$ |
7,076 |
|
|
$ |
5,326 |
|
| Less non-cash stock-based compensation |
|
|
(1,260 |
) |
|
|
(1,227 |
) |
|
|
(2,520 |
) |
|
|
(2,290 |
) |
| Operating costs and expenses excluding non-cash stock-based compensation |
|
$ |
2,207 |
|
|
$ |
1,543 |
|
|
$ |
4,556 |
|
|
$ |
3,036 |
|
| Operating costs and expenses excluding non-cash stock-based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
1,026 |
|
|
$ |
620 |
|
|
$ |
2,154 |
|
|
$ |
1,218 |
|
| Cancer Vaccines |
|
|
1,160 |
|
|
|
523 |
|
|
|
2,373 |
|
|
|
1,111 |
|
| Other |
|
|
21 |
|
|
|
400 |
|
|
|
29 |
|
|
|
707 |
|
| Total |
|
$ |
2,207 |
|
|
$ |
1,543 |
|
|
$ |
4,556 |
|
|
$ |
3,036 |
|
| Operating costs and expenses excluding non-cash share based compensation |
|
$ |
2,207 |
|
|
$ |
1,543 |
|
|
$ |
4,556 |
|
|
$ |
3,036 |
|
| |
|
April 30,
2024 |
|
|
October 31,
2023 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
11,314 |
|
|
$ |
7,523 |
|
| Cancer Vaccines |
|
|
12,778 |
|
|
|
17,215 |
|
| Other |
|
|
263 |
|
|
|
784 |
|
| Total |
|
$ |
24,355 |
|
|
$ |
25,522 |
|
| Total assets |
|
$ |
24,355 |
|
|
$ |
25,522 |
|
|